Related references
Note: Only part of the references are listed.Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine
Seah H. Lim et al.
ANNALS OF HEMATOLOGY (2012)
Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma
Umit Tapan et al.
LEUKEMIA & LYMPHOMA (2011)
Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma
Stephanie J. Carter et al.
LEUKEMIA RESEARCH (2011)
Bendamustine: Rescue of an Effective Antineoplastic Agent From the Mid-Twentieth Century
Lorenzo M. Leoni
SEMINARS IN HEMATOLOGY (2011)
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia
Anjana Elefante et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Bendamustine: something old, something new
Nishant Tageja et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Bendamustine A Review of its Use in the Management of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Karly P. Garnock-Jones
DRUGS (2010)
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents
Carlo Piccinni et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma
Izidore S. Lossos et al.
LEUKEMIA & LYMPHOMA (2010)
Incidence of hepatitis B reactivation following Rituximab therapy
Amr Hanbali et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2009)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
Arne Kolstad et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR
AL McNees et al.
JOURNAL OF CLINICAL VIROLOGY (2005)
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
AM Tsimberidou et al.
CANCER (2005)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
